Work

Potent CTL responses to conserved element of HIV to improve therapeutic DNA vaccine efficacy

Year: 2015

Type: article

Abstract: Conclusions: Vaccination with ChAdV63 and MVA.HIVconsv was a safe strategy to shift pre-existing immune response towards conserved regions of HIV-1 in a cohort of early-treated individuals, without inducing viral reactivation.Reservoir decay during first year of early-cART was not impacted by HIVconsv vaccinations.This is the first therapeutic vaccine trial that demonstrates a manipulation of CTL immunodominance pattern towards unmutated regions of HIV-1 and may facilitate clearance of the viral reservoir after HIV latency reactivation strategies.

Source: Journal of Virus Eradication

DOI: 10.1016/s2055-6640(20)31335-2

Authors: B.K. Felber, A. Valentin, J.I. Mullins, G.N. Pavlakis

Institutions: National Institutes of Health, National Cancer Institute, University of Washington

Language: English

Topic: HIV Research and Treatment

Subfield: Virology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,950